Pharmaceuticals

Global Fabry Disease Market Set for Strong Expansion, Reaching $3.27 Billion With 7.7% CAGR by 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the fabry disease market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Fabry Disease Market between 2026 and 2030?

The fabry disease market size has experienced robust expansion in recent years. It is projected to expand from $2.26 billion in 2025 to $2.43 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this historical growth include heightened awareness of rare genetic disorders, the approval of enzyme replacement therapies, the proliferation of specialty clinics, advancements in genetic screening programs, and an increase in diagnosis rates.

The Fabry disease market is set to experience significant growth in the coming years. It is projected to expand to $3.27 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This anticipated growth can be attributed to advancements in gene-based therapies, the expansion of newborn screening programs, increased healthcare spending on rare diseases, the rise of personalized medicine, and the development of next-generation oral therapies. Key trends during the forecast period include a growing adoption of enzyme replacement therapy, an increased focus on rare disease diagnosis, the expanding use of genetic testing for early detection, the proliferation of oral and adjunct therapies, and the implementation of more patient-centric treatment approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Which Drivers Are Expected To Impact The Fabry Disease Market During The Forecast Period?

The fabry disease market is expected to experience growth in the future due to an increasing focus on personalized medicine. This approach to treatment involves using information regarding a person’s genes, environment, and lifestyle to specifically tailor medical care and therapies for better outcomes. The rising emphasis on personalized medicine is driven by its ability to improve treatment effectiveness and reduce side effects by customizing therapies to individual patient needs. Personalized medicine assists in tailoring treatment plans based on a patient’s specific genetic mutation and disease severity, leading to improved outcomes and minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Consequently, a growing focus on personalized medicine is a key driver for the growth of the fabry disease market.

Which Segments Are Driving Activity In The Fabry Disease Market?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

Which Competitive Trends Are Impacting The Structure Of The Fabry Disease Market?

Major companies within the fabry disease market are actively pursuing the development of innovative therapies, such as PEGylated enzyme replacement therapy (ERT), with the goal of improving treatment efficacy, enhancing patient compliance, and mitigating the immunogenic responses linked to conventional ERTs. PEGylated enzyme replacement therapy (ERT) is an altered form of traditional ERT, where polyethylene glycol (PEG) chains are attached to the enzyme to boost its stability, extend its circulation time within the body, and lessen immune system reactions. For example, in May 2023, Chiesi Global Rare Diseases, a division of the Italy-based pharmaceutical company Chiesi Group, announced that the U.S. Food and Drug Administration (FDA), a US-based government agency, had approved PRX-102 (pegunigalsidase alfa) for treating adult Fabry disease patients. This approval was backed by a robust clinical program encompassing over 140 patients and long-term follow-up spanning up to 7.5 years, which established the therapy’s effectiveness in reducing renal Gb3 deposits and sustaining kidney function, while also demonstrating a favorable safety profile.

Which Leading Companies Dominate The Fabry Disease Market Share?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

How Does The Fabry Disease Market Perform Across Major Global Regions?

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Fabry Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Market 2026, By The Business Research Company

Fabry Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795